Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
ddp modified | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 88 | ||||||||||
answering dept short name | Attorney General | ||||||||||
answering dept sort name | Attorney General | ||||||||||
hansard heading | GlaxoSmithKline | ||||||||||
house id | 1 | ||||||||||
identifier | 199631 | ||||||||||
legislature |
|
||||||||||
parliament number | 55 | ||||||||||
question first answered |
|
||||||||||
question text | To ask the Attorney General, what the terms of reference are for the investigation by the Serious Fraud Office (SFO) into GlaxoSmithKline (GSK); whether the SFO will investigate (a) GSK's activities within the UK, (b) allegations of bribery of UK doctors, (c) promotion of Seroxat prescribing for children and (d) the 2002 CSM Expert Working Group on the safety of SSRI antidepressants; and whether there is a point of contact for members of the public who wish to help the SFO investigation. | ||||||||||
session |
|
||||||||||
session number | 4 | ||||||||||
tabling member constituency | Heywood and Middleton | ||||||||||
tabling member printed |
|
||||||||||
title | House of Commons Tabled Parliamentary Question 2014/15 199631 | ||||||||||
type |
|
||||||||||
uin | 199631 | ||||||||||
version | 2 | ||||||||||
written parliamentary question type | NamedDay | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher | 25259 | ||||||||||
tabling member |
|